NL-OMON55152已完成不适用
anadelumab for treatment of COVID-19 disease - COVID-LA
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 43
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 12 至 99（—）
入选标准
- •1. Patient is SARS-COV2 positive (PCR)
- •2. Without oxygen a saturation below 90% and or at least 3L/min oxygen dependent
- •3. Patient is 16 years and older
排除标准
- •1. Has previously participated in this study
- •2. Acute myocardial or cerebral ischemic event at time of enrolment
- •3. Receiving an agent that is specified as an intervention in this domain as a
- •usual medication prior to this hospitalization will exclude a patient from
- •receiving that agent
- •4. A baseline alanine aminotransferase or an aspartate aminotransferase that is
- •more than five times the upper limit of normal will result in exclusion from
- •receiving lanadelumab
- •5. Patient is known hypersensitive to full human monoclonal antibodies.
- •6. Patient is pregnant or breast feeding
研究者
相似试验
进行中（未招募）
1 期
anadelumab for treatment of COVID-19 diseaseCOVID-19MedDRA version: 23.0Level: PTClassification code 10084268Term: COVID-19System Organ Class: 10021881 - Infections and infestationsEUCTR2020-002472-12-NLRadboud University Medical Center80
已完成
1 期
Lanadelumab for Treatment of COVID-19 DiseaseCOVID-19NCT04422509Radboud University Medical Center43
终止
2 期
Adalimumab for coronavirus in community careCOVID-19 (SARS-CoV-2 infection)Infections and InfestationsISRCTN33260034niversity of Oxford
暂停
2 期
Convalescent Antibody-Mediated Treatment of COVID-19 Infections in Patients with B-cell dysfunction, a Randomized Trial (COVID-Compromise Study).NL-OMON51203Academisch Medisch Centrum86
招募中
不适用
COVID-CompromiseNL-OMON25136AmsterdamUMC86